Peng WX, Liu X, Wang QF, Zhou XY, Luo ZG, Hu XC. Heterochronic triple primary malignancies with Epstein-Barr virus infection and tumor protein 53 gene mutation: A case report and review of literature. World J Clin Cases 2021; 9(5): 1184-1195 [PMID: 33644183 DOI: 10.12998/wjcc.v9.i5.1184]
Corresponding Author of This Article
Xi-Chun Hu, MD, PhD, Professor, Department of Medical Oncology, Fudan University Shanghai Cancer Center, No. 270 Dongan Road, Xuhui District, Shanghai 200032, China. huxichun2017@163.com
Research Domain of This Article
Oncology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Wen-Xia Peng, Xin Liu, Zhi-Guo Luo, Xi-Chun Hu, Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China
Qi-Feng Wang, Xiao-Yan Zhou, Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China
Author contributions: Peng WX and Liu X performed the investigation and provided resources for the case report; Wang QF, Zhou XY, and Luo ZG provided resources for the case report; Peng WX was responsible for data collection and assembly; Hu XC reviewed and edited the article for important intellectual content; All authors participated in manuscript drafting and final approval for the version to be submitted.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016)
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xi-Chun Hu, MD, PhD, Professor, Department of Medical Oncology, Fudan University Shanghai Cancer Center, No. 270 Dongan Road, Xuhui District, Shanghai 200032, China. huxichun2017@163.com
Received: October 29, 2020 Peer-review started: October 29, 2020 First decision: November 20, 2020 Revised: December 2, 2020 Accepted: December 16, 2020 Article in press: December 16, 2020 Published online: February 16, 2021 Processing time: 92 Days and 21 Hours
Core Tip
Core Tip: The occurrence of triple heterochronic primary malignancies associated with Epstein-Barr virus (EBV) infection and genetic mutations is an extremely rare event. To the best of our knowledge, this is the first case of a 39-year-old male patient with triple heterochronic primary tumors including EBV-associated stomach cancer and nasopharyngeal cancer and tumor protein 53 mutant rectal carcinoma in the literature, and appropriate therapy for each primary cancer led to his good clinical outcome. This case further confirms the value of precision medicine; only a precise diagnosis can lead to appropriate treatment and good prognosis. Further research is needed to elucidate the role of EBV infection and the tumor protein 53 gene in the carcinogenesis of multiple primary malignant neoplasms.
